Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer.
Xóchitl Zambrano-EstradaBrianda Landaverde-QuirozAndrés A Dueñas-BocanegraMarco A De Paz-CamposGerardo Hernández-AlbertoBenjamín Solorio-PerusquiaManuel Trejo-MandujanoLaura Pérez-GuerreroEvangelina Delgado-GonzálezBrenda AnguianoCarmen AcevesPublished in: BMC veterinary research (2018)
The mDOX+I2 scheme improves the therapeutic outcome, diminishes the invasive capacity, attenuates the adverse events and increases disease-free survival. These data led us to propose mDOX+I2 as an effective treatment for canine mammary cancer.